[SMALL CELL CARCINOMA OF THE PROSTATE: A CASE REPORT OF RELATIVE LONG-TERM SURVIVAL]
| Autor: | Satoshi Washino, Tomoaki Miyagawa, Kimitoshi Saito, Mitsuhiro Nokubi, Masaru Hirai, Tsuzumi Konishi, Yutaka Kobayashi |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Male medicine.medical_specialty Time Factors Urology Antineoplastic Agents Small-cell carcinoma Multimodal Imaging Carboplatin chemistry.chemical_compound Fatal Outcome Prostate Internal medicine medicine Carcinoma Humans Anthracyclines Carcinoma Small Cell Aged Etoposide business.industry Prostatic Neoplasms Combination chemotherapy medicine.disease Regimen medicine.anatomical_structure chemistry Lymphatic Metastasis Positron-Emission Tomography Hormonal therapy business Tomography X-Ray Computed Amrubicin |
| Zdroj: | Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 106(4) |
| ISSN: | 0021-5287 |
| Popis: | Small cell carcinoma of the prostate (SCCP) is rare, and no standard treatment regimen has yet been established. The overall prognosis remains poor. We experienced a case who obtained relative long-term survival with two types of chemotherapy treatments. A 69-year-old man underwent combined androgen blockade (CAB) with a diagnosis of prostate adenocarcinoma (Gleason score = 5 + 3) that was staged T3bN1M1b (initial PSA = 352 ng/ml). Twenty-five months after hormonal therapy, the level of serum PSA had elapsed remain low, however, FDG-PET/CT revealed high value at the lymph node of para-aortic and pelvic lesion. The levels of serum NSE and Pro-GRP elevated, and a prostate re-biopsy revealed a small cell carcinoma. Therefore, he was treated with 12-cycles of combination chemotherapy consisting of etoposide and carboplatin. Then, disease has progressed, so he was changed to second line chemotherapy with amrubicin. He underwent 12-cycles chemotherapy with amrubicin, but he died of cancer 39 months after the initial treatment of SCCP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|